O-Methylcassythine

CAS No. 3984-10-9

O-Methylcassythine( ——— )

Catalog No. M38577 CAS No. 3984-10-9

O-Methylcassythine is an aporphine alkaloid, that can be isolated from Cassytha filiformis. O-Methylcassythine exhibits vasodilator activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    O-Methylcassythine
  • Note
    Research use only, not for human use.
  • Brief Description
    O-Methylcassythine is an aporphine alkaloid, that can be isolated from Cassytha filiformis. O-Methylcassythine exhibits vasodilator activity.
  • Description
    O-Methylcassythine is an aporphine alkaloid, that can be isolated from Cassytha filiformis. O-Methylcassythine exhibits vasodilator activity.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    3984-10-9
  • Formula Weight
    355.38
  • Molecular Formula
    C20H21NO5
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tsai TH, et al., Vasorelaxing alkaloids and flavonoids from Cassytha filiformis. J Nat Prod. 2008 Feb;71(2):289-91. ?
molnova catalog
related products
  • Stresscopin-Related ...

    Stresscopin-Related Peptide (6-43) (human)

  • MethADP

    MethADP (Adenosine 5'-(α,β-methylene)diphosphate) is a specific CD73 inhibitor that inhibits the enzyme ecto-5′-nucleotidase (ecto), which has been used in the study of neurological and cardiovascular diseases.

  • AZD0780

    AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.